**BioVision** 

02/14 For research use only

## Human CellExp™ CD30 /TNFRSF8, human recombinant

**CATALOG #**: 7389-10 10 μg

7389-50 50 μg

ALTERNATE NAMES: TNFRSF8, CD30, D1S166E, Ki-1

SOURCE: HEK 293 cells (Phe 19 - Lys 379)

**PURITY:** ≥ 95% by SDS-PAGE gel

**MOL. WEIGHT:** This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 39.3 kDa. The predicted N-terminus is Phe 19. DTT-reduced Protein migrates as 75-90 kDa due to glycosylation.

ENDOTOXIN LEVEL: <1 EU/µg by LAL method

FORM: Lyophilized


**FORMULATION:** Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.

**STORAGE CONDITIONS:** Store at -20°C. After reconstitution, aliquot and store at -20°C and use within 3 months. Avoid repeated freezing and thawing cycles.

**RECONSTITUTION:** Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50  $\mu$ g/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

**DESCRIPTION**: Human CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

**BIOLOGICAL ACTIVITY:** Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin's lymphoma cells. The ED<sub>50</sub> for this effect is typically  $0.5 - 2.5 \mu g/ml$  in the presence of 50 ng/ml of Recombinant Human CD30 Ligand.



Human recombinant CD30 /TNFRSF8

## **RELATED PRODUCTS:**

- Human CellExp™ CD223, human recombinant (Cat. No. 7278-10, -50)
- Human CellExp™ CD71, human recombinant (Cat. No. 7279-10, -50)
- Human CellExp™ CD273, human recombinant (Cat. No. 7369-10, -50)
- Human CellExp<sup>™</sup> CD33, human recombinant (Cat. No. 7370-10, -50)
- Human CellExp™ CD36, human recombinant (Cat. No. 7371-10, -50)
- Human CellExp™ CD87, human recombinant (Cat. No. 7372-20, -100)
- Human CellExp™ CD360, human recombinant (Cat. No. 7373-20, -100)
- Human CellExp™ CD244, human recombinant (Cat. No. 7374-10, -50)
- Human CellExp™ CD304, human recombinant (Cat. No. 7375-10)
- Human CellExp<sup>™</sup> CD319, human recombinant (Cat. No. 7376-10, -50)
- Human CellExp™ CD306, human recombinant (Cat. No. 7377-10, -50)
- Human CellExp™ CD84, human recombinant (Cat. No. 7378-10, -50)
- Human CellExp<sup>™</sup> CD111, human recombinant (Cat. No. 7379-10, -50)
- Human CellExp™ CD48, human recombinant (Cat. No. 7380-10, -50)

FOR RESEARCH USE ONLY! Not to be used in humans.

